Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
647 clinical trials found
Clinical trials

CAPLA Optional Long Term Follow Up

CAPLA trial: Catheter Ablation for persistent atrial fibrillation: A Multicentre randomised trial of Pulmonary vein isolation (PVI) vs PVI with posterior Left Atrial wall isolation (PWI) (ACTRN12616001436460)

Currently recruiting

CAPRI

Concentrated Albumin infusion Prior to Rescue Infliximab (CAPRI) in steroid refractory Acute Severe Ulcerative Colitis (ASUC), a randomized clinical trial (ACTRN12619001081101p)

Currently recruiting

CARISTA

Creating A Risk assessment biomarker tool to prevent Seasonal and Thunderstorm Asthma – CARISTA Study (NCT07055542)

CARISTA will test a new approach to predict risk for seasonal allergic asthma to identify treatable traits for preventing seasonal allergic asthma exacerbations to reduce the recurrent annual health threat of seasonal and thunderstorm asthma, address community and health care provider concerns and uncertainty regarding preventive treatment and management.
Currently recruiting

CARTITUDE-5

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy - CARTITUDE 5 (NCT04923893)

Currently recruiting

CARTITUDE-6

A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible (EMN28 68284528MMY3005) (NCT05257083)

Currently recruiting

CASPER

Colchicine After Stroke to Prevent Event Recurrence (CASPER) A randomised trial to evaluate the efficacy of oral Colchicine in high-risk patients with atherosclerosis-associated inflammation post-Stroke (ACTRN12621001408875)

Currently recruiting

CAST BM12

Study of using Cyclophosphamide After Sibling-donor allogeneic stem-cell Transplantation (CAST) in patients with acute leukaemia and myelodysplasia: a randomised study comparing cyclosporin and methotrexate to cyclosporin and post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis (ACTRN12618000505202)

Currently recruiting

CC93538-EE-001

A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Eosinophilic Esophagitis (NCT04753697)

No longer recruiting

CC93538-EE-002

A Phase 3, Multicenter, Multinational, Open-label Extension Study to Evaluate the Long-term safety of CC-93538 in Adult and adolescent subjects with eosinophilic esophagitis. (NCT04991935)

Currently recruiting

CCTL019E2301

A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or refractory follicular lymphoma (NCT05888493)

Currently recruiting

CEC-4/CEL

A phase IIb, double-blind, randomised, placebo-controlled trial evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet (ISRCTN79155276)

Currently recruiting

CECI830A12101

An open-label, multi-center, phase I/II study of ECI830 as a single agent and in combination with ribociclib and endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and advanced solid tumors (NCT06726148)

Currently recruiting

CELEBRATE

A Phase 1B study to evaluate the safety, tolerability and preliminary efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in patients with BRAF-mutant metastatic melanoma (The CELEBRATE study) (NCT04720768)

No longer recruiting

Celldex CDX0159-13

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment [EMBARQ – CSU2] (NCT06455202)

The CDX0159-13 study is designed to evaluate the safety and efficacy of Barzolvolimab in adult participants with chronic spontaneous urticaria (CSU) who still have symptoms despite H1-antihistamine treatment. Participants receive either trial medication or a placebo (something that looks like the trial drug but has no effect on the body), both administered as injections under the skin (subcutaneous). The treatment period will be approximately 52 weeks with all participants moved to active treatment (receiving treatment drug) after Week 24.

Currently recruiting

CG_MAGIC

Continuous Glucose Monitoring to Achieve euGlycemia in Cystic Fibrosis (Trial Not Registered)

Currently recruiting

CGIA632B12201 VITESS

A multicenter, randomized, double-blind, placebo-controlled, dose-range Phase II study to assess the efficacy and safety of GIA632 in patients with non-segmental vitiligo not adequately controlled with topical therapies [GIA632B12201 Vitiligo]. (NCT07431177)

This trial is investigating the safety and efficacy of GIA632 in adults with non-segmental vitiligo vs placebo. This trial lasts approximately one year and ongoing treatment is available for eligible participants. GIA632 is given via a subcut injection (injection into the stomach tissue) at fortnightly intervals.

Coming soon

CHAMPIONSHIP Trial

First In Human Study to Assess Safety and Efficacy of the ChampioNIR Drug Eluting Peripheral Stent in the Treatment of Patients with Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease (NCT06410313)

Peripheral arterial disease (PAD) is a condition which leads to narrowing and blockages in the large and medium-sized arteries which supply blood to your leg which typicalling requires angioplasty treatment. The ChampioNIR DES is a stent made of metal, coated with a mesh that can expand and which contains a drug called ridaforolimus. . Ridaforolimus stops cells from growing and replicating by attaching to a protein called mTOR, meaning that cells are less likely to build up around your stent and narrow your arteries.
Coming soon

CHARM

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction (NCT02864953)

Currently recruiting

CHECK MATE 9DW

A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma (NCT04039607)

Currently recruiting

Chugai DQB103CT

A PHASE IC, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, IMMUNOGENICITY, AND BIOLOGICAL EFFECTS OF DONQ52 IN CELIAC DISEASE PATIENTS WITH GLUTEN CHALLENGE (NCT05425446)

Currently recruiting
6 7 8 9 10